A Study to Assess LBL-007 in Combination With Toripalimab in Subjects With Advanced Melanoma
Status:
Recruiting
Trial end date:
2023-04-20
Target enrollment:
Participant gender:
Summary
This is a multi-center ,open-label, single-arm,dose-escalation,and extended phase I of
LBL-007 in combination with Toripalimab. The study is designed to assess the safety,
tolerability and efficacy of LBL-007 in combination with Toripalimab in the treatment of
unresectable or metastatic melanoma(including Cutaneous melanoma, Acral melanoma, Mucosal
melanoma, and melanoma of unknown primary）。